• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Neurogene Inc.

    12/11/24 4:05:09 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NGNE alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

    Neurogene Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.000001 par value

     

    (Title of Class of Securities)

     

    64135M105

     

    (CUSIP Number)

     

    December 4, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 64135M105 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    800,000*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    800,000*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    800,000*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4%*

    12

    TYPE OF REPORTING PERSON

     

    IA

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. 64135M105 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    800,000*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    800,000*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    800,000*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4%*

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. 64135M105 SCHEDULE 13G

     

    Item 1. (a) Name of Issuer

     

    Neurogene Inc. (the “Issuer”)

     

    Item 1. (b) Address of Issuer’s Principal Executive Offices

     

    535 W 24th Street, 5th Floor

    New York, NY 10011

     

    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
       
      This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.

     

    Item 2. (d) Title of Class of Securities

     

    Common Stock, $0.000001 par value (the “Common Stock”)

     

    Item 2. (e) CUSIP No.:

     

    64135M105

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

     

    N/A

     

     

     

     

    CUSIP No. 64135M105 SCHEDULE 13G

     

    Item 4. Ownership

     

    As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:

     

    (a) Amount Beneficially Owned: 800,000*

     

    (b) Percent of Class: 5.4%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 800,000*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 800,000*

     

    As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:

     

    (a) Amount Beneficially Owned: 800,000*

     

    (b) Percent of Class: 5.4%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 800,000*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 800,000*

     

    *The Firm is the investment manager to Commodore Master. As of December 4, 2024, the Firm may be deemed to beneficially own an aggregate of 800,000 shares of Common Stock of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 14,854,725 shares of Common Stock issued and outstanding as of November 13, 2024 based on information reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 18, 2024.

     

     

     

     

    CUSIP No. 64135M105 SCHEDULE 13G

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 64135M105 SCHEDULE 13G

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 11, 2024  
       
    Commodore Capital LP  
         
    By: /s/ Michael Kramarz  
    Michael Kramarz, Managing Partner  
         
    Commodore Capital Master LP  
         
    By: /s/ Michael Kramarz  
    Michael Kramarz, Authorized Signatory  

     

     

     

     

    Exhibit 1

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate.

     

    Dated: December 11, 2024  
       
    Commodore Capital LP  
         
    By: /s/ Michael Kramarz  
    Michael Kramarz, Managing Partner  
         
    Commodore Capital Master LP  
         
    By: /s/ Michael Kramarz  
    Michael Kramarz, Authorized Signatory  

     

     

     

    Get the next $NGNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NGNE

    DatePrice TargetRatingAnalyst
    5/16/2025$24.00Outperform → Neutral
    Robert W. Baird
    6/27/2024$65.00Outperform
    BMO Capital Markets
    6/11/2024$54.00Outperform
    Robert W. Baird
    4/29/2024$46.00Outperform
    Leerink Partners
    3/21/2024$61.00Outperform
    William Blair
    More analyst ratings

    $NGNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance wit

      6/6/25 4:01:00 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

      Oral presentation at ASGCT Annual Meeting to describe algorithm to monitor, detect and treat HLH, which can be adopted for AAV gene therapy Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting describing a monitoring and treatment algorithm intended to reverse the rare, severe hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH) that has been associated with systemic exposure to high doses of adeno-associated virus (AAV) gene therapy (>1E14 vg/kg). The

      5/16/25 7:00:00 AM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

      On track to provide registrational trial plan update for NGN-401 gene therapy for Rett syndrome in the first half of 2025 Continues to plan to provide clinical data update from ongoing NGN-401 Phase 1/2 trial in the second half of 2025 Cash runway into the second half of 2027 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates. "We have made significant progress in planning for our future registrational trial with NGN-401 gene therapy for Rett syndrome and expect to provide an up

      5/9/25 7:30:00 AM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neurogene Inc.

      SC 13G - Neurogene Inc. (0001404644) (Subject)

      12/11/24 4:05:09 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

      SC 13G/A - Neurogene Inc. (0001404644) (Subject)

      11/27/24 4:25:10 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

      SC 13G/A - Neurogene Inc. (0001404644) (Subject)

      11/14/24 4:53:08 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Neurogene downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Neurogene from Outperform to Neutral and set a new price target of $24.00

      5/16/25 8:03:18 AM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets initiated coverage on Neurogene with a new price target

      BMO Capital Markets initiated coverage of Neurogene with a rating of Outperform and set a new price target of $65.00

      6/27/24 7:50:19 AM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Neurogene with a new price target

      Robert W. Baird initiated coverage of Neurogene with a rating of Outperform and set a new price target of $54.00

      6/11/24 7:16:13 AM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGNE
    Financials

    Live finance-specific insights

    See more
    • Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

      All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire (RSBQ), ranging from 28 to 52 percent improvement from baseline All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data Low-dose NGN-401 well-tolerated with favorable safety profile Company plans to provide an update of registration

      11/11/24 4:01:00 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

      Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared. These data will also be presented in a late-breaking

      10/21/24 7:30:00 AM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGNE
    Leadership Updates

    Live Leadership Updates

    See more

    $NGNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

      Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. As previously disclosed, on November 11, 2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who received NGN-401 at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response tha

      11/18/24 6:45:00 AM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

      Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24 Strong financial position with runway into 2H:26 following reverse merger and private financing in December 2023 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates. "We started the year with strong execution in our Phase 1/2 NGN-401 gene therapy trial for female pediatric patients with Rett syndrom

      3/18/24 4:14:00 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Cobb Stuart sold $103,003 worth of shares (6,797 units at $15.15), decreasing direct ownership by 25% to 20,794 units (SEC Form 4)

      4 - Neurogene Inc. (0001404644) (Issuer)

      5/15/25 4:43:07 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Cobb Stuart was granted 7,200 shares, increasing direct ownership by 35% to 27,591 units (SEC Form 4)

      4 - Neurogene Inc. (0001404644) (Issuer)

      3/28/25 9:30:38 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CFO Cvijic Christine Mikail was granted 20,300 shares (SEC Form 4)

      4 - Neurogene Inc. (0001404644) (Issuer)

      3/28/25 9:29:40 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGNE
    SEC Filings

    See more
    • Neurogene Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Neurogene Inc. (0001404644) (Filer)

      6/12/25 4:20:40 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neurogene Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Neurogene Inc. (0001404644) (Filer)

      6/9/25 7:25:28 AM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Neurogene Inc.

      SCHEDULE 13G - Neurogene Inc. (0001404644) (Subject)

      5/15/25 4:19:38 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Samsara Biocapital Gp, Llc bought $1,259,623 worth of shares (48,770 units at $25.83) (SEC Form 4)

      4 - Neurogene Inc. (0001404644) (Issuer)

      11/27/24 4:39:29 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CFO Cvijic Christine Mikail bought $491,400 worth of shares (24,000 units at $20.48), increasing direct ownership by 45% to 76,844 units (SEC Form 4)

      4 - Neurogene Inc. (0001404644) (Issuer)

      11/25/24 9:29:29 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Mcminn Rachel bought $969,000 worth of shares (47,500 units at $20.40), increasing direct ownership by 4% to 1,297,859 units (SEC Form 4)

      4 - Neurogene Inc. (0001404644) (Issuer)

      11/25/24 9:29:04 PM ET
      $NGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care